Form 4: Lemaitre Vascular Director Martha Shadan Acquires Shares Through Dividend Equivalent Rights

Director Martha Shadan acquired shares of Lemaitre Vascular Inc. through the release of dividend equivalent rights associated with previously granted stock awards.

Summary

• Martha Shadan, a director at Lemaitre Vascular Inc., acquired shares of common stock on December 12, 2024.
• The shares were acquired through the release of dividend equivalent rights, which are tied to previously granted restricted stock units and performance stock units.
• A total of 3,459 shares were acquired, with 1,728 shares from restricted stock units and 1,731 shares from performance stock units.
• The acquisition price for these shares was $0, as they were obtained through the vesting of dividend equivalent rights.
• The dividend equivalent rights are economically equivalent to one share of the company's common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is a positive sign that a director is increasing their stake in the company, but it is not a major event that would significantly impact sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future performance.
• The vesting of stock awards and dividend equivalent rights aligns the director's interests with those of the shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The use of restricted stock units and performance stock units with dividend equivalent rights is a common practice in executive compensation across various industries, including medical device companies like Lemaitre Vascular.
• Similar companies such as Medtronic and Boston Scientific also use equity-based compensation to align management interests with shareholder value.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement for all publicly traded companies in the US.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows a director's increased stake in the company.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Lemaitre Vascular, Director, Martha Shadan, Stock Acquisition, Dividend Equivalent Rights, Restricted Stock Units, Performance Stock Units, Share Vesting, Insider Trading